Clinical Trials

    A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1)

    Investigator: Kai Sun

    Study Coordinator: Jawairia Jawed

    Status: Open Not Enrolling

    ClinicalTrials.gov Number: NCT05774951

    Phone: 346.356.3603

    Protocol Number: PRO00036788

    Description


    This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.